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Successful immunogenic apoptosis in experimental
cancer therapy depends on the induction of strong
host anti-tumor responses. Given that tumors are
often resistant to apoptosis, it is important to identify
alternative molecular mechanisms that elicit immu-
nogenic cell death. We have developed a genetic
model in which direct dimerization of FADD com-
bined with inducible expression of RIPK3 promotes
necroptosis. We report that necroptotic cancer cells
release damage-associated molecular patterns and
promote maturation of dendritic cells, the cross-
priming of cytotoxic T cells, and the production of
IFN-g in response to tumor antigen stimulation. Us-
ing both FADD-dependent and FADD-independent
RIPK3 induction systems, we demonstrate the effi-
cient vaccination potential of immunogenic necrop-
totic cells. Our study broadens the current concept
of immunogenic cell death and opens doors for the
development of new strategies in cancer therapy.INTRODUCTION
The discovery of immunogenic apoptosis (IA) underlines the
importance of tumor-host interaction, in which the activation
of an immune response, specifically toward malignant cancer
cells, results in a potent and long-lasting anti-cancer immu-
nity (Casares et al., 2005). IA is characterized by the release of
damage-associated molecular patterns (DAMPs), such as cell-
surface exposure of calreticulin (Garg et al., 2012a; Obeid
et al., 2007a), secretion of ATP (Garg et al., 2012b; Ghiringhelli
et al., 2009; Michaud et al., 2011), and release of the chro-
matin-binding protein high-mobility group B1 (HMGB1) (ApetohThis is an open access article under the CC BY-Net al., 2007; Yamazaki et al., 2014), each of which interact
with the phagocytic or scavenger receptors, e.g., LRP1 (calreti-
culin), purinergic receptors (ATP), and pattern-recognition re-
ceptors, such as TLR4 (HMGB1), respectively. Thus, inducing
IA in cancerous cells can be very beneficial in a therapeutic
setting because DAMPs induce a host anti-tumor immune
response. However, in order to overcome apoptosis resistance,
which is often observed in tumors (Hanahan and Weinberg,
2011), it is of great importance to find other ways to kill tumor
cells by triggering cell death modalities different from apoptosis.
Necrosis has long been described as a consequence of
extreme physiochemical stress, such as osmotic shock and
freezing-thawing (referred to throughout the text as ‘‘F/T’’), and
was therefore classified as uncontrolled or accidental cell death
(Kaczmarek et al., 2013). However, more recent findings have
demonstrated many different cellular stimuli that induce regu-
lated forms of necrosis, which follow defined steps and signaling
events reminiscent of a true cell death program. Necroptosis is
one form of regulated necrosis and is mediated by receptor-
interacting protein kinase-1 (RIPK1), RIPK3, and its substrate
mixed lineage kinase domain-like (MLKL) and has been reported
to contribute to inflammation under pathological conditions
(Degterev et al., 2005; He et al., 2013; Holler et al., 2000; Paspar-
akis and Vandenabeele, 2015; Pierdomenico et al., 2014).
In this study, we evaluated the immunogenicity of necroptosis
and tested its potential as an alternative approach in cancer
therapy. We observed that cancerous CT26 cells undergoing
necroptosis can be immunogenic in vitro and in vivo, where the
necroptotic cells served as potent immunizers in a prophylactic
tumor vaccination model. Vaccination with necroptotic cancer
cells effectively cross-primed cytotoxic CD8a+ T cells in vivo
and elicited the strong CT26 tumor antigen-specific production
of IFN-g ex vivo. The immunogenicity of necroptotic cells did
not correlate with the extent of NF-kB activation. These findings
identify necroptotic cancer cells as efficient inducers of an
adaptive immune response and show that necroptosis can beCell Reports 15, 1–14, April 12, 2016 ª2016 The Authors 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Generation of a Tet-On-Inducible Ligand-free Model of Necroptosis in Murine Tumor Cells
(A) Schematic presentation of the Tet-On-inducible constructs introduced into the CT26 cells (DD_RIPK3). A myristoylation signal (Myr), two copies of FKBP12,
a linker (L) to allow flexible dimerization, and the death domain (DD) of FADD. In a separate vector: full-length murine RIPK3, followed by an HA tag.
(legend continued on next page)
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Table 1. An Overview of the Inducible CT26 Cell Lines Made for
This Study, and Their Mode of Action on Stimulation with B/B
Homodimerizer and/or Doxycycline
CT26 Clone
Name
Treatment to Induce
Cell Death
Dimerization upon
Addition of B/B
Cell Death
Mode
FADD_RIPK3 doxycycline +
B/B dimerizer
FADD necroptosis
DD_RIPK3 doxycycline +
B/B dimerizer
DD necroptosis
DD_RIPK3 doxycycline DD necroptosis
RIPK3 doxycycline – necroptosis
Please cite this article in press as: Aaes et al., Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity, Cell Reports (2016),
http://dx.doi.org/10.1016/j.celrep.2016.03.037as immunogenic as known immunogenic apoptosis inducers,
such as mitoxantrone.
RESULTS
Generation of a Tet-On-Inducible Ligand-free Model of
Necroptosis in Murine Tumor Cells
Necroptosis is commonly induced by ligand-dependent activa-
tion of certain members of the TNFR and TLR families (Vanlange-
nakker et al., 2011). To circumvent the use of cell death-inducing
ligands or other immune active molecules that would not allow
us to evaluate the immune response resulting uniquely from
necroptosis induction, we opted for the use of inducible Tet-
On systems for the expression of the downstream necroptotic
effector proteins, allowing us to induce necroptosis indepen-
dently of any receptor activation. We, and others, previously re-
ported that induced expression and dimerization of the death
domain (DD) of FADD is sufficient to induce RIPK1-dependent
necroptosis in certain cells (Lohmann et al., 2009; Vanden
Berghe et al., 2004). Therefore, we initially tested this strategy
in the BALB/c mouse-derived CT26 cells, a colon carcinoma
cell line, which is commonly used to analyze the immunogenicity
of apoptosis-inducing drugs or cellular stress-inducing condi-
tions (Apetoh et al., 2007; Casares et al., 2005; Garg et al.,
2012b; Ghiringhelli et al., 2009; Michaud et al., 2011). For this
purpose, a doxycycline (doxy)-inducible vector containing the(B) Cells were stimulated with doxycycline for 4 or 18 hr and co-stimulated with B
features (cleaved Caspase-8, cleaved Caspase-3, or cleaved PARP) during necro
as a positive control. In the condition of stimulation with doxy + B/B, pro-caspase
B/B addition, because these cells were already pre-treated for 18 hr with doxycyc
At this rather late stage of cell death, one characteristic is the degradation of the pr
et al., 2001). In the condition of stimulation with doxy alone for 4 hr, pro-caspase-
early stage of cell death. Note that CT26 cells do not express RIPK3 in the non-ind
(lane 3) is due to a slight leakiness of the RIPK3 construct. The western blot sho
(C) Cell death progressionmeasured by SYTOXGreen fluorescence in theDD_RIP
during the cell death progression. Pool of seven independent experiments.
(D) Time-lapse microscopy reveals the permeabilization, but no blebbing, of the pl
overexpression anddimerizationofDD_RIPK3 (upper) or themereoverexpressiono
(E) Immunoprecipitation of RIPK3 shows RIPK1-MLKL-RIPK3 complex formatio
homodimerizer. The anti-FADD antibody recognizes endogenous FADD (30 kDa)
(42 kDa).
(F) Immunoprecipitation of FADD reveals a FADD-RIPK1 complex upon overexpre
RIPK1modifications are also seen (note the smear above the RIPK1 band at the 4
is no complex formation. *The remnant RIPK3 band is still visible from the previo
See also Figure S1 and Movies S1 and S2.DD of FADD, coupled to two FKBP12 domains (which allows
DD multimerization on addition of a homodimerizer referred to
as B/B), was introduced into the murine CT26 cells. However,
we found that, in contrast to other cell lines, the mere expression
and dimerization of DD in CT26 cells did not induce cell death
(data not shown). We found out that this difference originates
from the fact that RIPK3 is not expressed in the CT26 cells. In
order to circumvent this deficiency, we introduced a doxy-induc-
ible vector containing RIPK3 in addition to the DD-containing
construct (Figure 1A; Table 1). Stimulation of these cells (referred
to as DD_RIPK3) with doxy triggered caspase-independent cell
death (Figures 1B and 1C), which is accelerated in the presence
of B/B (Figure 1C). Phase-contrast and time-lapse microscopy
(Figure 1D; Movies S1 and S2) further revealed rounding up
and swelling of cells (oncosis) and plasma membrane permeabi-
lization, two hallmarks of necrotic cell death (Majno and Joris,
1995). Immunoprecipitation of RIPK3 shows that necroptosis in-
duction is associated with the formation of a complex consisting
of RIPK1, RIPK3, and MLKL (Figure 1E) (Cho et al., 2009; He
et al., 2009; Li et al., 2012; Pasparakis and Vandenabeele,
2015; Sun et al., 2012). Surprisingly, the additional multimeriza-
tion of the DD domains of FADD, which results in accelerated
necroptosis (Figure 1C), did not increase but instead decreased
the interaction of RIPK3 with RIPK1 and MLKL (Figure 1E). In
contrast, DD multimerization greatly enhanced recruitment of
RIPK1 to FADD (Figure 1F) and seems to be associated with
RIPK1 modifications, which have previously been reported to
correlate with RIPK1-induced death (Dondelinger et al., 2013;
Dynek et al., 2010). Importantly, we found that RIPK1 was
required for cell death induction in the absence of forcedDDmul-
timerization (Figures S1A and S1E). Repression of MLKL (Fig-
ure S1E) did not block cell death progression (Figures S1A and
S1C), but rather induced a switch to apoptosis, both in the pres-
ence and in the absence of forced DD multimerization (Figures
S1B and S1D), as previously described for TNF-induced necrop-
tosis (Remijsen et al., 2014). Additionally, we detect phosphory-
lation of MLKL on Ser345 (Murphy et al., 2013; Wang et al., 2014)
upon stimulation with doxy, as well as with doxy + B/B (Fig-
ure S1F). All these data suggest the induction of necroptosis in
DD_RIPK3 cells in both inducible conditions./B, where indicated during the last 0.5–4 hr. Western blot shows no apoptotic
ptosis induction in the DD_RIPK3 cells. FADD-overexpressing CT26 cells serve
-3 and pro-caspase-8 start to disappear upon cell death induction at 1 hr after
line, which induces massive induction of cell death (up to 80% of Sytox+ cells).
oteins and their passive release, which has been previously reported (Denecker
3 and pro-caspase-8 were still detected on western blot, because this is still an
uced conditions. The faint band observed in the unstimulated DD_RIPK3 cells
wn here is representative for one of three independent experiments.
K3 cells upon stimulation with doxy or doxy +B/B. NoDEVD activity is detected
asma membrane during cell death, measured by SYTOX Green and induced by
fDD_RIPK3 (lower). The imagesarederived fromMoviesS1andS2, respectively.
n upon doxy-induced necroptosis; this is abolished upon addition of the B/B
, which in this cell line corresponds to the overexpressed DD-FKBP12 protein
ssion of DD_RIPK3, combined with the dimerization of DD. Under this condition
hr co-induction with doxy and B/B). Without addition of the B/B dimerizer, there
us membrane exposure.
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Figure 2. Necroptotic Cancerous Cells Are Phagocytized and Induce BMDC Maturation
(A) Phagocytosis assay shows effective uptake by BMDCs of necroptotic cells killed by doxy. (Left) Representative flow cytometry dot plots show the uptake of
CMFDA-labeled dead cell material by BMDCs (CD11c+CMFDA+ double-positive cells). (Right) The quantification is the pool of triplicates from three independent
experiments and represents the mean value + SEM. UT, untreated (live DD_RIPK3) cells.
(legend continued on next page)
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Next, we tested the immunogenic properties of these necrop-
totic tumor cells in vitro. By co-culturing untreated DD_RIPK3
cells (live cells) or doxy-treated DD_RIPK3 cells (necroptotic
cells) with primary bone marrow-derived dendritic cells
(BMDCs), we observed that the necroptotic cells, and not the
live cells, were effectively engulfed by BMDCs (Figure 2A).
Maturation of DCs is characterized by the upregulation of sur-
face co-stimulatory ligands, of which MHC-II is vital for the prim-
ing of naive T cells and for mounting an anti-tumor immune
response (Ma et al., 2013). We found that the necroptotic
(DD_RIPK3) cells, but not the same amount of live or accidental
necrotic (F/T) cells, alter the maturation status of the BMDCs.
BMDCs co-cultured with necroptotic cells in a 1:10 ratio showed
maturation as indicated by upregulation of the co-stimulatory li-
gands MHCII+CD86+ (Figures 2B and 2D) and MHCII+CD80+
(Figures 2C and 2E) when compared with untreated BMDCs or
with BMDCs co-cultured with live DD_RIPK3 cells. Co-culture
with the same amount of F/T accidental necrotic cells apparently
did not alter the maturation status of BMDCs. Together, these
in vitro results indicate that necroptotic DD_RIPK3 cells are
potent inducers of BMDC-mediated phagocytic clearance and
phenotypic maturation.
Necroptotic Cells Induce Anti-tumor Immunogenicity
with the Cross-Priming and Proliferation of CD8+ T Cells
In order to test the ability of necroptotic tumor cells to acti-
vate the adaptive immune system, we used a well-established
prophylactic tumor vaccination model in immunocompetent
BALB/c mice (Figure 3A) (Casares et al., 2005; Garg et al.,
2012b; Ghiringhelli et al., 2009; Kepp et al., 2014; Michaud
et al., 2011; Obeid et al., 2007a). Immunization of mice with
necroptotic DD_RIPK3 cells, induced by doxy and B/B, or by
doxy treatment alone, prevented tumor growth at the challenge
site (Figures 3B and 3C). Notably, the mice that were vacci-
nated with the same number of F/T cells remained significantly
less tumor-free on the challenge site (Figures 3C and 3D),
indicating that accidental necrotic cells apparently are less
immunogenic than are necroptotic DD_RIPK3 cells killed by
stimulation with doxy. In line with this, the immunogenicity of
F/T accidental necrotic tumor cells was completely lost when
the mice were immunized with half the amount of cells (Fig-
ure 3D), whereas the necroptotic cells remained equally immu-
nogenic, independently of the way necroptosis was elicited,
viz. by overexpression of DD and RIPK3, or the same overex-
pression including active dimerization of DD. Moreover, the tu-
mors growing on the challenge site of the unvaccinated (PBS)(B) Representative dot plots (quantified in Figure 2D) showing the gating and
necroptotic (doxy + B/B), untreated (UT) DD_RIPK3 cells, accidental necrotic F/T
(C) Representative dot plots (quantified in Figure 2E) showing the gating and per
(doxy + B/B), untreated (UT) DD_RIPK3 cells, accidental necrotic F/T, or untreat
(D) Co-culture of BMDCs with necroptotic or accidental necrotic F/T cells in two
expressed as the mean value + SEM of four independent experiments (in which
(E) Co-culture of BMDCs with necroptotic and accidental necrotic F/T cells in t
expressed as themean value + SEM of four independent experiments (in which th
with lipopolysaccharide (LPS) served as a positive control.mice were significantly larger than the tumors occurring on
the mice receiving vaccines with necroptotic cells (Figure 3E),
confirming that necroptotic cells induce a potent immune
response in vivo.
To further examine the adaptive immune response to the anti-
tumor vaccination achieved with the necroptotic DD_RIPK3
cells, wemeasured the cross-priming, proliferation, and cytokine
release of cytotoxic T cells isolated from the draining inguinal
lymph nodes of vaccinated mice (Figure 3F). We found that the
draining lymph nodes of mice immunized with necroptotic
DD_RIPK3 cells killed by doxy alone or by doxy and B/B con-
tained tumor antigen-specific proliferating cytotoxic CD8a+
T cells (Figures 3G and 3H), demonstrating the ability of necrop-
totic cells to activate the adaptive immune system in vivo.
We also observed that tumor antigen-specific CD8a+ T cells
had statistically significant higher tetramer staining intensity in
mice vaccinated with DD_RIPK3 necroptotic tumor cells
compared with unvaccinated mice, as well as compared with
mice that were immunized with F/T accidentally necrotic cells
(Figure 3I). Interestingly, this cross-priming in vivo was absent
or below the detection limit in mice vaccinated with acciden-
tally necrotic cells, confirming the lower immunogenicity of F/T
accidental necrotic cells. Correspondingly, vaccination of mice
with DD_RIPK3 necroptotic cells also primed the immune cells
for IFN-g production in an ex vivo re-stimulation assay with an
H2-Ld-restricted peptide (AH-1) (Huang et al., 1996) of both
draining inguinal lymph nodes and spleens (Figures 3J and
3K). Note that the detection of tetramer staining is a subject of
variation in our analysis (Figures 3G and 3I), probably reflecting
the lack of sensitivity of such staining or differences in timing of
the immune response in the individual mice, because mouse
samples that are negative for one parameter do score positive
for all other parameters examined.
DAMPs and Chemokines Are Secreted from Necroptotic
Cells
One of the main characteristics of immunogenic apoptosis is the
spatiotemporally coordinated emission of DAMPs such as ATP
and HMGB1, which have a beneficial role in anticancer therapy
owing to their interaction with the immune system (Apetoh
et al., 2007; Garg et al., 2012b; Michaud et al., 2011). By
mimicking in vitro the prophylactic vaccination setup, in which
the dead cells are washed in PBS before injection into the mice,
we observed that the DD_RIPK3 cells treated with doxy ± B/B
continue to die up to 24 hr after being re-seeded in fresh medium
without inducer and dimerizer (Figures S2A, S2B, and S2F). After
re-seeding, the cells continued to release lactate dehydroge-
nase (LDH) and HMGB1 (Figures S2C and S2D). In addition,percentage of CD11c+CD86+MHC-II+ BMDCs in co-culture ratio 1:10 with
CT26 wild-type (WT) cells, or untreated (UT) CT26 WT cells.
centage of CD11c+CD80+MHC-II+ BMDCs in co-culture 1:10 with necroptotic
ed (UT) CT26 WT cells.
different ratios (1:1 and 1:10). Percentage of CD11c+CD86+MHC-II+ BMDCs
three of the experiments included F/T cells).
wo different ratios (1:1 and 1:10). Percentage of CD11c+CD80+MHC-II+ cells
ree of the experiments included F/T cells). In Figures 2B–2E, BMDCs stimulated
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Figure 3. Necroptotic Cells Induce Anti-tumor Immunogenicity with Cross-Priming and Proliferation of CD8a+ T Cells
(A) The prophylactic tumor vaccination model used in vivo in Figures 3C, 3D, and 4F.
(B) Cell death measured by flow cytometry of the cells used for immunization (representative results from one experiment) of the mice in Figure 3C. The cells used
for immunization were stimulated (with doxycycline, mitoxantrone, or co-stimulated with doxycycline + B/B) and re-suspended in PBS before injection.
(C) Necroptosis induced by doxy or by doxy + B/B triggers an anti-tumor immune response when immunizing mice with 3.0 M cells. For a positive control, we
vaccinated themicewith 3M immunogenic apoptotic cells, whichwere killed bymitoxantrone (MTX) (Obeid et al., 2007a). Pool of eight independent experiments;
n = total number ofmice per group. The statistical difference fromPBS is shown for each vaccination group or in-between groups as indicated by the vertical bars.
(legend continued on next page)
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http://dx.doi.org/10.1016/j.celrep.2016.03.037progressive secretion and accumulation of the chemokine
CXCL1was also observed in these cultures (Figure S2E). Consis-
tent with the higher upregulation of Cxcl1 (Figure 4B), we also
detect higher amounts of CXCL1 secreted upon co-stimulation
of DD_RIPK3 cells with the B/B homodimerizer. CXCL1 is de-
tected in the conditioned medium from only regulated necrop-
totic cells, and not in that of accidental necrotic (F/T) cells;
whereas the passive release of e.g., ATP (Figure S2G) is detected
in the conditioned medium of both regulated and accidental ne-
crosis, as well as to a minor degree in that of untreated cells.
The latter is probably due to spontaneous cell death caused by
the over-growth of cells 24 hr after re-seeding.
One of the common prerequisites of immunogenicity triggered
by most IA-inducing stimuli is the induction of PERK-mediated
endoplasmic reticulum (ER) stress (Krysko et al., 2012), which
leads to calreticulin exposure on the cell surface, and thereby
acts as an ‘‘eat-me’’ signal (Garg et al., 2012b; Panaretakis
et al., 2009). Yet, we found that the necroptotic tumor cells do
not show any pronounced features of ER stress (Figure S3),
suggesting that in our DD_RIPK3 cells the immunogenicity of
necroptosis is mainly disengaged from any ER stress.
Role of NF-kB Activation in Immunogenicity of
Necroptosis
Cytokine secretion by dying tumor cells has been proven to
enhance the anti-tumor immunity and thereby also the clear-
ance of tumor cells (Jinushi et al., 2008). Recently, it has
been shown that NF-kB signaling in NIH 3T3 fibroblasts under-
going necroptosis is a requirement for efficient cross-priming
of CD8+ T cells (Yatim et al., 2015). Therefore, we also exam-
ined the status of NF-kB activation in CT26 cells undergoing
necroptosis. We only observed clear NF-kB activation when
necroptosis was associated with induced DD dimerization
as shown by phosphorylation and concomitant degradation
of IkBa (Figure 4A). These results correlate with those of an
RT-qPCR expression analysis focusing on a panel of NF-kB-
regulated inflammatory genes, in which we observed a higher
upregulation of cytokine/chemokine-encoding genes when
necroptosis is induced by doxy and B/B rather than by doxy
only (Figure 4B).The one-star difference between the two DD_RIPK3 groups (±B/B) corresponds t
p value of 0.0205.
(D) Immunization with only 1.5 M necroptotic cells is highly efficient. Pool of tw
number of mice per group. The statistical difference from PBS is shown for each
(E) The size of the tumors growing on the challenge site of the mice that were use
two experiments shown in Figure 3D. The statistical difference from PBS is show
(F) The experimental setup preceding the analysis of T cell proliferation, cross
(cf. Figures 3G–3K). Each dot in Figures 3G–3K represents one mouse, and each
(G) The proportion of proliferating (BrdU+) tumor antigen-specific (Tetramer-AH1
mice (see labels on the x axis). Mean value with 95% CI of four independent exp
(H) The proportion of tumor antigen-specific (Tetramer-AH1+) CD8a+ T cells derive
axis). Mean value with 95% CI of five independent experiments; n = 18–20 mice
(I) The median fluorescence intensity (MFI) of tumor antigen-specific (Tetramer-A
(see labels on the x axis). Mean value with 95% CI of five independent experime
(J) IFN-g ELISpot assay using the inguinal draining lymph nodes of immunized
independent experiments; n = 11–12 mice per vaccination group.
(K) IFN-gELISpot assay using the spleens of immunizedmice (see labels on x axis)
11–12 mice per vaccination group. No statistically significant difference was meas
in Figures 3G–3J.To better distinguish between the contribution of RIPK3 over-
expression with and without DD dimerization to NF-kB activa-
tion, we generated two additional Tet-On inducible CT26 cell
lines (Figure 4C; Table 1), expressing RIPK3 or a combination
of RIPK3 with dimerizable FADD (FADD_RIPK3). The combined
expression and dimerization of FADD in the presence of RIPK3
(Figure 4D; Movie S3), or the mere overexpression of RIPK3
(Figure 4D; Movie S4), led to necroptotic cell death as observed
by the absence of DEVD activity (Figure 4D), phosphorylation of
MLKL Ser345 (Figure 4E), oncosis morphology and plasma
membrane permeabilization (Movies S3 and S4). Notably,
both additional inducible necroptosis cell lines (FADD_RIPK3;
RIPK3) were also immunogenic when used to immunize immu-
nocompetent mice in the in vivo prophylactic tumor vaccination
model (Figure 4F). Moreover, the immunogenicity of these two
CT26 cell lines (FADD_RIPK3; RIPK3) used in the prophylactic
tumor vaccination model (in the experiment shown in Figure 4F)
also elicited an efficient anti-tumor immune response, because
the tumors growing on the challenge site of these mice were
significantly smaller than those on the unvaccinated mice (Fig-
ure 4G). However, we clearly observed NF-kB activation (phos-
phorylation and concomitant degradation of IkBa) only in the
cell line where necroptosis was associated with the dimerization
of FADD (Figure 4H), again suggesting that the extent of NF-kB
activation is uncorrelated with the observed immunogenicity
induced by necroptotic cells in our model.
Although it has been reported that RIPK3 can mediate NLRP3
inflammasome activation and IL-1b activation (Kang et al., 2013;
Vince et al., 2012), we could not detect IL-1b, neither at mRNA
level nor at protein level in necroptotic DD_RIPK3 cells (induced
with doxy + B/B) and their supernatant respectively (data not
shown), thereby excluding the role of IL-1b in immunogenicity
in our system.
DISCUSSION
Our results demonstrate that cancerous cells undergoing
necroptosis can be immunogenic. This immunogenicity was
shown in vitro, where upon co-culture with BMDCs, the necrop-
totic cells were phagocytized and resulted in the phenotypico a p value of 0.0492. The difference between DD_RIPK3 doxy and MTX has a
o independent experiments (immunization with F/T was done once); n = total
vaccination group.
d in the prophylactic tumor vaccination experiments. Data represent one of the
n for each vaccination group.
-priming, and IFN-g production of BALB/c mice immunized with 3.0 M cells
error bar represents the 95% confidence interval (CI).
+) CD8a+ T cells derived from the inguinal draining lymph nodes of immunized
eriments; n = 14–16 mice per vaccination group.
d from the inguinal draining lymph nodes of immunizedmice (see labels on the x
per vaccination group.
H1+) CD8a+ T cells from the inguinal draining lymph nodes of immunized mice
nts; n = 18–20 mice per vaccination group.
mice (see labels on x axis). Mean value with 95% CI of triplicates from three
.Mean valuewith 95%CI of triplicates from three independent experiments; n =
ured between PBS and F/T in Figures 3G–3K or between doxy and doxy + B/B
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Figure 4. Role of NF-kB Activation in Immunogenicity of Necroptosis
(A) Western blot shows NF-kB activation (phosphorylation of IkBa [p-IkBa] and its subsequent degradation [IkBa]) upon stimulation with doxy + B/B, but less
when stimulating with doxy only. Representative blot of three independent experiments.
(legend continued on next page)
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http://dx.doi.org/10.1016/j.celrep.2016.03.037maturation of BMDCs, as well as in vivo, where necroptotic cells
served as potent immunizers in a prophylactic tumor vaccination
model. Necroptotic cells induced effective cross-priming of
cytotoxic CD8a+ T cells in vivo, and they mediated a strong
CT26 tumor antigen-specific production of IFN-g ex vivo. In
our experiments, the immunogenicity of necroptotic cells does
not seem to correlate with the level of NF-kB activation in vitro.
Thus, taken together, necroptotic cancer cells appear to be
potent inducers of an adaptive immune response and mediate
efficient anti-tumor immunity.
Several models of necroptosis in tumor cells have been
described, and they are mainly based on ligand-dependent
activation of certain members of the TNFR (e.g., TNF) and TLR
families (e.g., LPS and PolyI:C) (Krysko et al., 2006; Takemura
et al., 2015; Vanlangenakker et al., 2011). However, when used
in vivo, these necroptosis-inducing ligands may also target
the host immune system and therefore do not allow evaluation
of the immune response resulting uniquely from necroptosis
induction. To circumvent this ligand transfer in our study, we
developed a ligand-free tetracycline-inducible gene expression
system, which enables us to conditionally induce RIPK3-depen-
dent necroptosis in syngeneic murine colon carcinoma CT26
cells. This cell line has already been widely used to characterize
the ability of anti-cancer therapies to induce immunogenic
apoptosis (Casares et al., 2005; Garg et al., 2012b; Michaud
et al., 2011; Obeid et al., 2007b). RIPK3 was the necroptosis-
inducer of choice, given that it is required for activation of the
necroptotic pathway (Cho et al., 2009; Zhang et al., 2009). We
also expressed the dimerizable death domain (DD) of FADD as
a platform favoring necroptosis (Vanden Berghe et al., 2004). In
this study, we also provide evidence that at low cell numbers
used for vaccination, the immunogenicity of necrotic cancer cells
is more efficient when the cells undergo a cell death program
rather than die by F/T accidental necrosis. F/T accidental
necrotic cells are immunogenic only when used in high numbers
for vaccination (3.0 M cells per mouse), but yet they neither
induce cross-priming of CD8a+ T cells nor do they give rise to
tumor antigen-specific IFN-g production.
Our data are in line with a recently published study (Yatim
et al., 2015), in which it is shown that necroptosis induced by(B) qRT-PCR data shows the upregulation of NF-kB-regulated inflammation-ass
normalized relative quantities, fold induction compared to untreated DD_RIPK3 ce
(or from two independent experiments for 4-h doxy only).
(C) The Tet-On-inducible constructs introduced into the CT26 cells, which were
(D) Cell death progression measured by SYTOX Green fluorescence and caspas
along with the overexpression of RIPK3, or by overexpression of RIPK3 induces
(E) Western blot shows phosphorylation of MLKL (p-MLKL) on Ser345 on indu
During apoptosis induction by mitoxantrone (MTX) in WT cells, we detect no RIP
experiments.
(F) In the prophylactic tumor vaccination model, necroptosis induced by the overe
is immunogenic. The mice were immunized with 3.0 M dead cells. Pool of two ind
difference from PBS is shown for each vaccination group.
(G) The size of the tumors growing on the challenge site of the mice that were used
the two experiments shown in Figure 4F. The statistical difference from PBS is s
(H) Western blot analysis shows NF-kB activation during necroptosis mainly unde
unstimulated RIPK3 (lane 3) and RIPK3_FADD (lane 8) cells is due to a slight lea
experiments.
See also Movies S3 and S4.overexpression and dimerization of RIPK3, but not accidental
necrotic cells, induces the efficient cross-priming of CD8a+
T cells. Together, the data of Yatim et al. (2015) (in NIH 3T3
fibroblast cells) and our results (in CT26 colon carcinoma
cells) strongly suggest that necroptosis is immunogenic in a
cell-type-independent manner. Additionally, our findings also
suggest that, as opposed to IA-induced (Panaretakis et al.,
2009) and hypericin-based photodynamic therapy (Garg et al.,
2012b), the immunogenic necroptosis induced in our system is
apparently not associated with any pronounced ER stress or
PERK activation. Nevertheless, the necroptotic cells are strongly
immunogenic. It is therefore conceivable that other mechanisms
than merely ER stress or PERK activation must be a requisition
for an efficient anti-tumor response.
It has been shown that dimerization of RIPK3 in fibroblasts
leads to NF-kB activation in necroptotic cells, and interestingly
it was demonstrated that blocking this NF-kB signaling reduced
the cross-priming efficiency of CD8+ T cells (Yatim et al., 2015).
However, in our study we observed that immunogenicity of
necroptotic cancerous cells does not correlate with the activa-
tion status of NF-kB signaling measured in vitro. Prominent
NF-kB activation appeared, in our system, to be dependent on
the active dimerization of full-length FADD or of the FADD death
domains (DD). Concomitantly, the overexpression of RIPK3,
together with dimerization of DD, resulted in an upregulation of
several genes, which are transcriptionally induced by NF-kB,
as opposed to necroptosis induced without DD dimerization in
the same cell line. Whether this phenomenon is applicable to
other cell death-inducing systems with/without FADD or DD
dimerization is a subject for future investigation. Importantly,
a main difference between the findings of Yatim et al. (2015)
and those of our study is the way the dying cells were adminis-
tered as vaccine: Yatim et al. (2015) injected treated living fibro-
blasts (MEFs and NIH 3T3 cells), which further die in vivo over
a longer period of time. In contrast, we injected PBS-washed
dead cancerous cells. It is conceivable that our bolus injection
of dead cells requires fewer NF-kB-dependent factors because
enough DAMPs or other signals are present to overrule the
NF-kB dependency. This diverting feature is of great interest
and will be further investigated in our future experiments.ociated genes during necroptosis induced by doxy + B/B or by doxy (average
lls). Presented values are the means of triplicate samples from one experiment
used in Figures 4D–4H.
e activity by DEVD-AMC cleavage. Overexpression and dimerization of FADD,
cell death with no DEVD activity. Pool of three independent experiments.
ction of FADD_RIPK3 cells with doxy + B/B or RIPK3 cells with doxy alone.
K3 or p-MLKL expression. Representative blot from one of two independent
xpression of RIPK3 or by the overexpression and dimerization of FADD_RIPK3
ependent experiments; n = the total number of mice per group. The statistical
in the prophylactic tumor vaccination experiments. Data represent the pool of
hown for each vaccination group.
r conditions in which FADD is dimerized. The faint RIPK3 bands observed in the
kiness of the RIPK3 construct. Representative blot of one of two independent
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lines (He et al., 2009), as well as in primary human cancers, such
as breast cancer (Koo et al., 2015) and acute myeloid leuke-
mia (Nugues et al., 2014), a strategy might indeed be to restore
RIPK3 expression in the cancer cells through the application of
hypomethylating agents (Koo et al., 2015), or via (oncolytic) vi-
rus-mediated expression of RIPK3. One way to induce RIPK3-
dependent necrotic cell death is by 5-aminolevulinic acid-based
photodynamic therapy (Fulda, 2014), and it may therefore be
a possible mode of cell death induction in apoptosis-resistant
cancers.
To date, the observation of immunogenic dying cancer cells
is restricted to immunogenic apoptosis (Casares et al., 2005;
Garg et al., 2012a, 2012b; Ghiringhelli et al., 2009; Michaud
et al., 2011; Obeid et al., 2007a). Our study indicates that
(1) necroptotic cancerous cells release DAMPs (ATP and
HMGB1), induce maturation of dendritic cells and production
of IFN-g by T cells, and mediate anti-tumor immunity, (2) induc-
tion of a regulated cell death program is required for efficient
immunogenicity of dead cells, and (3) immunogenicity of necrop-
tosis does not correlate with the extent of NF-kB activation
status. Our finding that necroptotic tumor cells are strongly
immunogenic broadens the current concept of immunogenic
cell death. In a clinical setting, this will become beneficial for
patients with apoptosis-resistant cancers, providing that phar-
macological strategies are redesigned to compensate for defec-
tive cell death signaling by inducing alternative immunogenic cell
modalities, such as necroptosis.EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
The murine colon carcinoma CT26 cells and its derivates were cultured in
DMEM (GIBCO), supplemented with 10% heat-inactivated fetal calf serum
(FCS) (Life Technologies), L-glutamine (0.03%), and sodium pyruvate
(0.4 mM), all LPS-free products. Cells were cultured at 37C in the presence
of 5% CO2 and were tested for the absence of mycoplasma contamination
on a regular basis.
The FADD_RIPK3 cell line was first obtained by transduction of CT26 cells
with pDG2-flag-rtTA3-puro-Myr-2FKBP12-L-FADD plasmid. This is a tetracy-
cline-inducible derivative of pLenti6 (Life Technologies) also containing a puro-
mycin selection marker, in which the coding sequence for a myristoylation
(Myr)-targeting peptide, two tandem repeats of FKBP12 (Clontech), a short
linker peptide (L, GSGGGS), and the full-length murine cDNA of FADD (Open
Biosystems, BC021400) were cloned. Upon lentiviral transduction, the stably
transduced cells were selected with 9 mg/ml puromycin and transduced again
with a tetracycline-inducible pDG1-HA-blast-RIPK3 in which mouse cDNA of
RIPK3 was cloned. pDG1 RIPK3-HA-blast contains a blasticidin selection
marker and the influenza HA epitope from ARIAD. Then the stably transduced
cells were selected with 9 mg/ml puromycin and 7 mg/ml blasticidin, and clones
were obtained by limited dilution. Necroptosis was induced by 1 mg/ml doxy-
cycline and 10 nM of B/B homodimerizer (Clontech).
The DD_RIPK3 cell line was first generated by transduction of CT26 cells
with pDG2-flag-rtTA3-puro-Myr-2FKBP12-L-DD plasmid. This plasmid is
tetracycline inducible and contains the coding sequence for a Myr-targeting
peptide, two tandem repeats of FKBP12 (Clontech), a short linker peptide
(L, GSGGGS), and the death domain (amino acids 80–205) of the murine
FADD (Open Biosystems, BC021400). Upon lentiviral transduction, the stably
transduced cells were selected with 9 mg/ml puromycin and transduced again
with a tetracycline-inducible pDG2 RIPK3-HA-blast in which mouse cDNA of
RIPK3 was cloned. pDG1 RIPK3-HA-blast contains a blasticidin selection
marker and the influenza HA epitope from ARIAD. Then the stably transduced10 Cell Reports 15, 1–14, April 12, 2016cells were selected with 9 mg/ml puromycin and 7 mg/ml blasticidin, and clones
were obtained by limited dilution. Necroptosis was induced by 1 mg/ml doxy-
cycline and 10 nM of B/B homodimerizer or by induction with 1 mg/ml doxycy-
cline only.
Transducing CT26 cells with pDG2-flag-rtTA3-puro-mRIPK3 generated
the RIPK3-overexpressing cells. Stably transduced cells were selected with
9 mg/ml puromycin, and clones were obtained by limited dilution. Necroptosis
was induced by stimulation with 1 mg/ml doxycycline.
Cell Death Assay on FLUOstar OMEGA
Cell death was analyzed on a FLUOstar OMEGA (BMG Labtech). 6,000 to
10,000 cells were seeded in a transparent 96-well plate. 2 mM SYTOX Green
nucleic acid stain (Molecular Probes, S7020) and 33 mM Ac-DEVD-AMC (Pep-
tanova, 3171-V) were added to the cells, and the cells were then stimulated
with doxycycline or doxycycline + B/B as described above.
Maximal cell death was obtained by treatment with Triton X-100 (0.05%).
This allowed the expression of cell death as a percent of the control of maximal
SYTOX Green fluorescence (excitation 485 nm, emission 520 nm). If the exec-
utor caspases-3/-7 are activated during cell death, they cleave Ac-DEVD-AMC
only upon plasma membrane rupture, resulting in the release of fluorescent
7-amino-4-methylcoumarin (AMC) (excitation 355 nm, emission 460 nm).
The DEVD activity is expressed as fold induction compared to the maximal
fluorescence intensity value.
Cell Death Assay by Flow Cytometry
The cells were washed in Annexin V binding buffer (BD Bioscences, 556454),
followed by a staining with SYTOX Blue Nucleic Acid Stain (Molecular Probes,
S11348) and APC Annexin V (BD Biosciences, 550474) or Annexin V, Alexa
Fluor 488 conjugate (Molecular Probes, A13201) and run on a BD FACSVerse
flow cytometer. The data were analyzed using FlowJo software.
Small Interfering RNA-Mediated Knockdown
DD_RIPK3 cells were transiently transfected with Dharmacon small interfering
RNAs against MLKL (GenBank: XM_924585) GAGAUCCAGUUCAACGAUA,
RIPK1 (GenBank: NM_009068) UCACCAAUGUUGCAGGAUA, or nonspe-
cific (D-001810-10-20). 3,000 cells were seeded in 96-well (for FLUOstar), or
24-well plates (for western blotting), and were transfected in accordance
with the manufacturer’s protocols by using Dharmafect-1 transfection reagent
(Thermo Fisher Scientific, T-2001-03). The cell death in DD_RIPK3 cells was
induced by doxycycline or doxycycline + B/B, and the percentage of cell death
and caspase-3/7 activity were determined as described above. The efficiency
of knockdown was analyzed by western blotting.
Live-Cell Imaging
Cells were seeded in an eight-well chamber (iBidi), with 15,000 cells per well in
200 ml complete growth medium. Cell death was induced just before imaging,
and cell death was monitored by SYTOX Green (10 nM, Molecular Probes).
Live-cell imaging was performed on a Leica Sp5 AOBS confocal microscope
(Leica), using a 403 HCX PL Apo UV 1.25 na oil objective. Cells were imaged
for bright field and SYTOX Green using the 488 line of a Multi-line Argon Laser.
Images were acquired in a sequential mode. Images were captured in three
frames per well every 20 min, and the pinhole was opened to 2 AU to prevent
phototoxicity and photobleaching; likewise, the scanner was set at a speed of
700 Hz. Different focal planes were set at 1-mm intervals. From each image
stack, maximum intensity projections for SYTOX Green and montages of the
multi-tiff time series and two-channel overlays were made using ImageJ
1.49 m, a public domain imaging software.
Western Blot Analysis
Samples were lysed in Laemmli buffer containing 50 mM Tris HCl (pH 6.8), 2%
SDS, and 10% glycerol. The protein concentration for each sample was
determined using a NanoDrop 1000 spectrophotometer in accordance with
the manufacturer’s recommendations. The proteins were separated by SDS-
PAGE and transferred to nitrocellulose membranes.
Western blotting was performed with anti-FKBP12 (Thermo Scientific
PA1-026A), anti-RIPK3 (Sigma Aldrich, R4277), anti-Caspase 8 (Abnova,
MAB3429), anti-Cleaved caspase-8 (Cell Signaling Technology, 9429),
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Signaling Technology, 9544), anti-actin (MP Biomedicals, 69100), anti-phos-
pho-IkB-a (Cell Signaling Technology, 9246), anti-IkB-a (Santa Cruz Biotech-
nology, sc-371), anti-RIPK3 (ProSci, 2283), anti-tubulin HRP (Abcam,
ab21058), anti-FADD (Santa Cruz, sc-6036), anti-RIPK1 (BD Biosciences,
610459), anti-HA (Covance, MMS-101R), anti-MLKL (Millipore, MABC604),
anti-phospho-MLKL S345 (Abcam, ab196436), anti-phospho-PERK (Cell
Signaling Technology, 3179S), anti-PERK (Cell Signaling Technology,
3192S), anti-phospho-eIF2a (Cell Signaling Technology, 3597S), anti-eIF2a
(Cell Signaling Technology, 2103S), anti-CHOP (Cell Signaling Technology,
2895S), anti-BiP (Cell Signaling Technology, 3183S), and anti-XBP1 (Abcam,
ab37152).
Amersham ECL HRP-linked sheep anti-mouse immunoglobulin G (IgG)
(NA931), donkey anti-rabbit IgG (NA934), or goat anti-rat IgG (NA935) second-
ary antibodies were from GE Healthcare Life Sciences. After incubation with
the appropriate secondary antibodies conjugated to horseradish peroxidase,
blots were revealed using ECL western blotting substrate (Pierce, 32106), or
Western Lightning plus-ECL (PerkinElmer, NEL105001EA).
Immunoprecipitation
1.25 3 106 CT26 DD_RIPK3 cells were seeded per 10-cm petri dish. The next
day, the cells were stimulated with doxycycline, doxycycline + B/B added
simultaneously, or doxycycline +B/B added for the last half an hour. After treat-
ment with the indicated triggers, the cells were washed with PBS and lysed in
NP-40 lysis buffer (150mMNaCl, 1%NP-40, 10%glycerol, and10mMTris-HCl
[pH, 8]), supplemented with cOmplete, EDTA-free protease inhibitor cocktail
tablets (Roche, 11873580001), and PhosSTOP phosphatase inhibitor cocktail
tablets (Roche, 04906837001). Immunoprecipitation was done overnight using
protein G-coupled anti-FADD (Santa Cruz, sc-6036), protein A-coupled anti-
Caspase-8 (homemade antibody), or protein A-coupled anti-RIPK3 (Pro-Sci,
2283). After all immunoprecipitations, the beads were washed three times in
NP-40 lysis buffer, and the immunoprecipitated proteins were eluted by adding
60 ml of 23 Laemmli buffer to the beads. Complexes were subsequently
analyzed by immunoblotting (20 ml protein loaded per lane).
LDH, ATP, HMGB1, and CXCL1 Release after Cell Reseeding
DD_RIPK3 cells were seeded in 96-well plates (for LDH release assay) and in
10-cmpetri dishes (for ATP, HMGB1, andCXCL1 release assays), left to adhere
for4hr, and then treatedwith the indicateddrugs foranother18hr.Supernatants
and cells were collected from all conditions. The remaining cells were washed
once in PBS and reseeded in 24-well plates or in a 96-well plate (for the LDH
assay). After the indicated time points, supernatant was collected and cleared
from dying tumor cells by centrifugation (1,500 rpm, for 5 min; except for the
ATPassay, as centrifugation can stimulate release, independently from stimula-
tion and cell death). The supernatant was either used immediately for LDHcyto-
toxicity assay (Cayman Chemical) and ATP quantification (ATP Bioluminescent
Assay Kit, Sigma-Aldrich) or frozen at 20C for later use for HMGB1 quantifi-
cation by an ELISA kit (IBL-Hamburg), and CXCL1 quantification using a
bead-based multiplex immunoassay (ProcartaPlex, eBioscience). All assays
were performed in accordance with the respective manufacturers’ instructions.
LDH and HMGB1 were quantified using the iMARK microplate absorbance
reader (Bio-Rad), and forHMGB1, thedatawereanalyzedwithaFourParameter
Logistic Curve Fit (MyAssays.com). ATPwasmeasuredwith theGloMax 96-mi-
croplate luminometer (Promega). CXCL1 release was measured with Bio-Plex
200 Systems (Bio-Rad) and analyzed with the Bio-Plex Manager software.
Generation of Mouse BMDCs
BMDCs were differentiated from the femurs and tibias of 7-week-old BALB/c
mice for 8 days using RPMI 1640 medium (GIBCO), supplemented with 5%
heat-inactivated fetal calf serum, L-glutamine (0.03%), sodium pyruvate
(0.4 mM), 2-mercapthoethanol (50 mM), and mGM-CSF (20 ng/ml). Fresh cul-
ture medium was added on day 3, and on day 6 the medium was refreshed.
Phagocytosis Assay
The target cells, CT26 DD_RIPK3 cells, were labeled with 1 mM CellTracker
Green CMFDA (Molecular Probes, C7025) for 30 min and were then either
left untreated or induced to cell death by stimulation with doxycycline for18 hr. The cells were collected, washed, and co-cultured with BMDCs in a ratio
1:1 for 2 hr. Next, the co-cultured cells were harvested, incubated with a
mouse Fc block (BD PharMingen, 553142), immunostained with APC-anti-
CD11c (BD PharMingen, 550261), and, finally, analyzed by flow cytometry
on the BD FACSVerse. Analysis was performed using FlowJo (v.10.0.8)
software. True uptake of CMFDA-labeled dead cell material by BMDCs was
determined using a gating strategy that allows analysis of only single cells
and was determined as CD11c+CMFDA+ double-positive cells. Cell death of
the CT26 cells was determined by flow cytometry as described above and
was analyzed concurrently with the phagocytosis assay samples.
Analysis of BMDCs Surface-Marker Expression
Cell death was induced in the DD_RIPK3 cells on the addition of doxycycline
and B/B homodimerizer for 18 hr. The dead DD_RIPK3 cells were collected,
washed in RPMI culture medium, and co-cultured with 50,000 BMDCs in
two different ratios: 1:1 and 1:10. In parallel, CT26 WT cells were subjected
three times to freeze-thaw cycles and co-cultured with BMDCs in the same
ratios and cell numbers as the DD_RIPK3 cells. Co-culture was performed
for 18 hr at 37C in six-well plates with 2.5 ml RPMI culture medium.
Control BMDCs were left untreated or stimulated with 100 ng/ml LPS
(Sigma Aldrich, L2630). After 18 hr co-culture, all cells were collected, spun
down (400 3 g, for 6 min, 4C), and washed once in PBS (GIBCO DPBS,
Life Technologies, 14190-094) + 0.5% FCS. Dead cells were excluded
from the flow cytometry analysis by staining with SYTOX Blue (Molecular
Probes, S11348). Maturation of BMDCs was analyzed by immunostaining
using APC-anti-CD11c (BD PharMingen, 550261), FITC-anti-MHC class II
(eBioscience, 11-5321), PE-Cy7-anti-CD86 (BD PharMingen, 560582),
PerCP-Cy5.5-anti-CD80 (Molecular Probes, A14895), and mouse Fc block
(BD PharMingen, 553142).
Gatingstrategy:SinglecellswereobtainedbygatingonFSC-AversusFSC-H,
followed by SSC-A versus SSC-H. Dead cells were excluded by SYTOX Blue.
Mature BMDCs cells were identified as a percent of CD11c+MHCII+CD86+
and CD11c+MHCII+CD80+. All samples were acquired on the BD FACSVerse
flow cytometer and analyzed with FlowJo 10.0.8 software.
Mice
Female BALB/c mice (6–7 weeks old) were purchased from Harlan Labora-
tories (Netherlands) or from Charles River Laboratories (France) and were
housed in specific pathogen-free (SPF) conditions. All experiments were per-
formed in accordance with the guidelines of the local Ethics Committee of
Ghent University.
In Vivo Prophylactic Tumor Vaccination
CT26 cells were seeded on 15-cm petri dishes, and cell death was induced
in vitro, either via the inducible systems for 18–24 hr or by incubating the cells
with 2 mMmitoxantrone (Sigma,M6545) for 24 hr. After cell death induction, the
cells were collected, washed once in PBS (GIBCO DPBS, Life Technologies,
14190-094), and re-suspended in the desired concentration in PBS. Mice
were inoculated subcutaneously with 3 3 106 or 1.5 3 106 dying CT26 cells
or with PBS on the left flank side. Accidental necrosis was induced by subject-
ing the CT26 cells, already resuspended in the desired PBS volume, three
times to freeze-thaw cycles (dry ice/37C). On day 8 after vaccination, the
mice were challenged subcutaneously (s.c.) on the opposite flank with 5 3
105 live CT26 cells. Tumor growth on the challenge site was evaluated using
an electronic caliper for up to 4 weeks after the challenge. Micewere sacrificed
when tumors became necrotic or exceeded 2,000 mm3.
Analysis of T Cell Cross-Priming and Proliferation
Mice were injected s.c. with 33 106 dying CT26 DD_RIPK3 cells or PBS at the
tail base, which enabled a clear isolation of the draining inguinal lymph nodes.
After 17 days, 0.8 mg/ml bromodeoxyuridine (BrdU, Sigma-Aldrich, B5002)
was added to the drinking water. 4 days later, thus 3weeks after immunization,
the mice were sacrificed, and the spleens and inguinal draining lymph nodes
were isolated. The spleens were treated twice with ACK Lysing Buffer (Lonza,
10-548E), and along with the lymph node samples, the cells were spun
down (400 3 g, for 7 min, at 4C), before they were resuspended in PBS
(GIBCO DPBS, Life Technologies, 14190-094). The cells were stained withCell Reports 15, 1–14, April 12, 2016 11
Please cite this article in press as: Aaes et al., Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity, Cell Reports (2016),
http://dx.doi.org/10.1016/j.celrep.2016.03.037MHC Dextramer (H-2 Ld/SPSYVYHQF-PE, Immudex, JG3294-PE), followed
by anti-CD4 (BD Pharmingen, 557307), anti-CD8a (BD Pharmingen, 553036),
anti-CD3e (BD Pharmingen, 558214), anti-CD19 (eBiosciences, 56-0193-82),
mouse Fc block (BD Pharmingen, 553142), and LIVE/DEAD Fixable Aqua
Dead Cell Stain Kit (Molecular Probes, L34957).
Fixation and BrdU staining was performed in accordance with the manufac-
turer’s protocol (eBioscience, 8817-6600-42). Compensation was made with
the use of UltraComp eBeads (eBioscience, 01-2222-42). Flow cytometry
acquisition was performed with the BD LSR II HTS flow cytometer (BD Biosci-
ences). Data were analyzed using FlowJo (v.10.0.8) software.
Ex Vivo Restimulation of Lymphocytes and IFN-g ELISpot Assay
Spleens and inguinal draining lymph nodes were isolated from mice 3 weeks
after immunization (see Analysis of T Cell Cross-Priming and Proliferation).
Following lysis of erythrocytes, 1.0 3 105 lymph node cells from the draining
lymph nodes or 2.5 3 105 splenocytes were seeded per well on an IFN-g
capture antibody-coated 96-well polyvinylidene fluoride-bottomed plate (Milli-
pore, MSIPS4510), and the cells were restimulated for 24 hr with 5 mg/ml of
AH-1 peptide (SPSYVYHQF, tebu-bio, AS-64798); stimulation with 4 mg/ml
concanavalin A type IV served as a positive control (Sigma-Aldrich, C2010).
The murine IFN-g ELISpot assay was performed in accordance with the
manufacturer’s instructions (Diaclone, 862.031.010). Spots were counted
using an A.EL.VIS 4 Plate ELISPOT-Reader (v.2.1) and quantified with the
A.EL.VIS Eli.Analyze software. The presented values (each dot) are the mean
values of triplicate samples of AH-1 peptide-stimulated cells with background
RPMI only stimulation subtracted from one mouse. The overall mean (black
horizontal bar) and 95% CI (error bars) for each immunization is calculated
for all of the mice from the three independent experiments.
qRT-PCR Analysis of Cytokine Expression
5 3 105 CT26 DD_RIPK3 cells were seeded in 6-cm dishes in 3 ml complete
growth medium and were left untreated or stimulated with doxycycline or
doxycycline + B/B for two different time points. RNA was isolated using
the RNeasy Plus Mini Kit in accordance with the manufacturer’s instructions
(QIAGEN, 74134). Cell death was analyzed in parallel by flow cytometry.
RNA concentration wasmeasured on the NanoDrop 1000 spectrophotometer,
followed by RNA quality assessment using Agilent RNA 6000 Nano Reagents
and Nano Chips (Agilent Technologies, 5067-1511) and analyzed with the Agi-
lent 2100 Bioanalyzer (Agilent Technologies). cDNA synthesis was performed
with the iScript cDNA Synthesis Kit (Bio-Rad 170-8891), and gene expression
was assessed with gene specific primers using Sensifast SYBR No-Rox kit
(Bioline BIO-98020) on a LightCycler 480 instrument (Roche). Data were
analyzed with qbase+ (Biogazelle) generating normalized relative quantities.
The results shown represent the fold increase compared with the values ob-
tained with the unstimulated DD_RIPK3 cells.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism (v.6.0). The phagocy-
tosis assay was analyzed by a Mann-Whitney non-parametric t test. The
BMDCs activation and maturation assay was analyzed using a two-way
ANOVA test. Kaplan-Meier survival curves showed the time line for tumor
occurrence and were analyzed by the log-rank Mantel-Cox test. Differences
in tumor volume on the mice in the vaccination experiments were analyzed
with a two-way ANOVAwith Tukey’s multiple comparisons test. The T cell pro-
liferation and cross-priming experiments and the IFN-g ELISpot assays were
all analyzed with an ordinary one-way ANOVA with Tukey’s multiple compar-
isons test. The DAMPsmeasurements (ATP and HMGB1) were analyzed using
a Mann-Whitney non-parametric t test. The difference in therapeutic tumor
treatment was calculated using two-way ANOVA. *p value < 0.05, **p value <
0.01, ***p value < 0.001, ****p value < 0.0001. No exclusion criteria were used.
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